Delivering on the promise of decentralized clinical trials requires a comprehensive strategy that incorporates multiple aspects of the patients’ experience from start to finish. The challenge lies in creating a truly interoperable solution that integrates direct patient feedback with objective data derived from a multitude of digital health technologies including wearables, sensors and medical devices.
Register for this webinar to hear an expert from Meditata discuss strategies for engaging patients, defining a data strategy and real-world case studies spanning multiple therapeutic areas.
Ben Schlatka, VP, Digital Biomarker Solutions, Medidata
Ben Schlatka joined Medidata in 2020 through Medidata’s acquisition of MC10’s Digital Biomarker Business. After beginning his career as a corporate “intrapreneur” at IBM, Mr. Schlatka grew a series of successful startups including Volunteer Solutions.org (Sold to the United Way) and Nantero (Sold to Lockheed Martin). Most recently, Mr. Schlatka was co-founder & CEO of MC10, a pioneer in sensors and new end point development in clinical research. Mr. Schlatka is passionate about using digital technologies to transform the lives of patients, in both clinical research and clinical practice. He holds an MBA from the Harvard Business School and frequently lectures on the formation of disruptive science-based businesses.Message Presenter
Who Should Attend?
- Clinical Operations
- Data Management
- Data Science
What You Will Learn
The focus of this webinar will include:
- Strategies for engaging patients before, during and after trials
- Defining a unified data strategy that includes data ingestion and normalization
- Addressing data privacy concerns based on varying global requirements
- Real-world case studies spanning multiple therapeutic areas
Medidata, a Dassault Systèmes company, is leading the digital transformation of life sciences, creating hope for millions of patients by helping to generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes.